GUWAHATI: Finally, a silver lining even as the dark cloud of COVID-19 pandemic continues to hover of the globe. India-based Glenmark Pharmaceuticals has launched antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 symptoms.
FabiFlu is the first oral Favipiravir-approved medication for the treatment of Covid-19, the company said in a statement. The drug has received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) on Friday.
“This approval comes at a time when Covid-19 cases in India are spiralling like never before, putting tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha reportedly said.
The drug, called FabiFlu, will be marketed in some north Indian states soon. The drug will soon be available in hospitals and stores in a pack of 34 oral tables at moderately affordable price of Rs 103 per tablet.
